statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Buy Rating Confirmed: Expanding Potential of Nkarta's NKX019 in SLE Treatment

Analyst Emily Bodnar from H.C. Wainwright maintained a Buy rating on Nkarta (NKTX Research Report) and keeping the price target at $23.00. Emily...

Nkarta Announces New President and Strategic Executive Shifts

The latest announcement is out from Nkarta (NKTX). Nkarta, Inc. has appointed Nadir Mahmood, Ph.D., previously CEO of Rezo Therapeutics, as its new...

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of Investors

Glancy Prongay & Murray LLP (GPM), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Nkarta, Inc. (Nkarta or the Company) (NASDAQ...

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of Investors

Law Offices of Howard G. Smith announces an investigation on behalf of Nkarta, Inc. (Nkarta or the Company) (NASDAQ: NKTX) investors concerning the Companys possible violations of federal securities...

The Law Offices of Frank R. Cruz Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of Investors

The Law Offices of Frank R. Cruz announces an investigation of Nkarta, Inc. (Nkarta or the Company) (NASDAQ: NKTX) on behalf of investors concerning the Companys possible violations of federal...

Nkarta to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced...

Nkarta (NASDAQ:NKTX) Stock Price Down 5.7%

Nkarta, Inc. (NASDAQ:NKTX - Get Free Report)'s share price fell 5.7% on Tuesday . The company traded as low as $10.11 and last traded at $10.20. 68,322 shares were traded during mid-day trading, a...

Huge Insider Buying From Buffett, an NFL Team Owner, a New CEO

Yet again, the Oracle of Omaha has bolstered his stake in a media giant's tracking stocks. However, Warren Buffett was not the only one making notable insider purchases in the past week or so. An NFL...

Nkarta, Inc. (NASDAQ:NKTX) Director Simeon George Acquires 2,000,000 Shares

Nkarta, Inc. (NASDAQ:NKTX  Get Free Report) Director Simeon George purchased 2,000,000 shares of Nkarta stock in a transaction that occurred on Wednesday, March 27th. The shares were acquired...

Equities Analysts Offer Predictions for Nkarta, Inc.'s Q1 2024 Earnings (NASDAQ:NKTX)

Nkarta, Inc. (NASDAQ:NKTX  Free Report)  Investment analysts at HC Wainwright boosted their Q1 2024 earnings per share estimates for shares of Nkarta in a report released on Monday...

Nkarta, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of natural killer cell therapies for the treatment of cancer. The firm’s product include NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes, and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company was founded by Dario Campana in 2005 and is headquartered in South San Francisco, CA.

Volume	408,625.00
52-Wk High	$16.24
52-Wk Low	$1.28

NKTX Nkarta Inc

About

Feed

News

Sentiment

Earnings

Fundamentals